Physician profile
Damon D Tanton
NPI 1952429615
$1,160,920.48
in general payments reported to CMS, 2019-2025
26 companies · $218K in 2025
The $218K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179K · 2020: $172K · 2021: $156K · 2022: $174K · 2023: $140K · 2024: $121K · 2025: $218K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $408K · Travel and Lodging: $36K · Consulting Fee: $22K · Food and Beverage: $11K · Acquisitions: $1,945 · Education: $51.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $407,608.50 |
| Travel and Lodging | $35,898.56 |
| Consulting Fee | $21,661.80 |
| Food and Beverage | $11,362.29 |
| Acquisitions | $1,945.45 |
| Education | $51.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $443,990.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $341,160.99 | 2019-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160,737.97 | 2019-2025 | Jardiance |
| Amgen INC. | $63,378.65 | 2024-2025 | Tepezza, Uplizna |
| Medtronic Minimed, INC. | $41,422.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $33,792.28 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26,405.66 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $13,397.10 | 2019 | |
| Insulet Corporation | $12,669.51 | 2019-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $7,239.00 | 2020 | |
| Eli Lilly and Company | $4,712.50 | 2021 | |
| Medtronic, INC. | $4,326.33 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Sanofi-Aventis U.S. LLC | $2,365.10 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,456.77 | 2019 | |
| Horizon Therapeutics Plc | $964.02 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $798.10 | 2019-2024 | Freestyle Libre, Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $662.59 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Companion Medical, INC. | $400.32 | 2019-2020 | |
| Cequr Corporation | $200.99 | 2021 | |
| Johnson & Johnson Health Care Systems INC. | $200.38 | 2019 | |
| Dexcom, INC. | $199.95 | 2019-2023 | Dexcom G6 Transmitter |
| Bigfoot Biomedical INC | $146.13 | 2022-2023 | Unity Diabetes Management System |
| Corcept Therapeutics | $125.00 | 2021 | |
| Sanofi Pasteur INC. | $91.98 | 2019 | |
| Senseonics, Incorporated | $70.00 | 2019 | |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Tanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.